OncoMatch/Clinical Trials/NCT04799002
Topotecan and Melphalan for Retinoblastoma
Is NCT04799002 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Topotecan and Melphalan for retinoblastoma.
Treatment: Topotecan · Melphalan — The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.
Check if I qualifyEligibility summary
For patients with retinoblastoma.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
Frequently asked questions
Is NCT04799002 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify